Lv3
250 积分 2025-01-30 加入
LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study
22天前
已完结
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
25天前
已完结
CABINET presents cabozantinib as a new treatment option for NETs
1个月前
已完结
Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
1个月前
已完结
PP047 Concomitant 177Lu-DOTATATE and low dose capecitabine versus 177Lu-DOTATATE alone in patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumours – a randomized controlled trial
1个月前
已完结
Abstracts
1个月前
已完结
Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial
1个月前
已完结
92: [177Lu]Lu-Dota-Tate as First-Line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): The NETTER-2 Study
1个月前
已完结
Corrigendum to ‘Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)’ [European Journal of Cancer 169 (2022) 1–9]
2个月前
已完结
皖公网安备34019202002308
